Swedish–British pharma leader shaping oncology, vaccines, and global health
Scientists at Oxford have begun Phase I trials of a ChAdOx BDBV vaccine for Bundibugyo Ebola in healthy UK adults, with 620,000 doses stockpiled and partnerships for African trials. The trial monitors safety and immune response for a year as the outbreak expands in the Democratic Republic of Congo.
The White House has proposed phased tariffs on imported generic medicines, arguing for a U.S.-based manufacturing boost. The plan starts with two years of zero tariffs, followed by 100% and then 200% levies, to spur domestic production. Industry groups warn the move could raise prices for patients while onshoring efforts face structural hurdles. Major manufacturers say margins are thin and shifting production could take years.
Regulators are reviewing a BMJ study linking GLP-1 receptor agonists to a higher risk of alopecia. The study compares hair-loss rates in GLP-1 users against SGLT-2 and DPP-4 inhibitors, with findings suggesting a 37% higher risk versus SGLT-2 and 68% higher versus DPP-4. Hair loss appears non-scarring and potentially reversible, often tied to weight loss and nutritional factors.
GSK has announced a 1.9 billion cost-cutting programme and a shift of more than 1,000 scientists to a new Cambridge R&D campus from Stevenage by 2029, part of broader plans to cut costs and expand late-stage trials.
EY has warned the UK economy could slip into recession if Hormuz remains closed, while a reopening could keep growth resilient at 0.9% in 2026 and 1.2% in 2027. The outlook shifts with oil prices easing and talks of a potential AstraZeneca–BMS merger, set against a backdrop of manufacturing activity data and a stretched timetable for a takeover.
AstraZeneca has been linked to talks with Bristol Myers Squibb on a potential mega-merger. Reports say talks are ongoing and could form one of the industry’s largest deals, but regulatory hurdles and integration risks loom large.
A roundup of recent reports shows how debt, housing costs, and consumer spend patterns shape the US financial landscape. Redfin and Zillow data indicate ongoing affordability stress in housing, while consumer debt and money-management trends are highlighted by CNBC and independent outlets. The mix suggests a cautious, debt-aware economy.
AstraZeneca has not confirmed talks with Bristol Myers Squibb on a potential $400bn mega-merger, despite earlier reports. The markets rallied and fell as investors digest the possibility, with analysis suggesting mega-deals face antitrust and integration risks. AZ’s strategy centers on accelerating U.S. presence while leveraging its strong oncology franchise.
Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.
Global markets have steadied as US retail data suggests consumer spending is softer while inflation trends remain in check. Traders are watching for Federal Reserve guidance as major indices hover near records after a week of mixed signals across equities, bonds and currencies.
Two unvaccinated residents in Pennsylvania have died from measles, triggering a public health debate. Governor Shapiro says vaccinations could have averted the deaths, while RFK Jr. questions the figures, fueling a political row that experts warn could hinder responses to the outbreak.
The FDA has approved daraxonrasib, sold as Rasonque by Revolution Medicines, for adults with previously treated or ineligible metastatic pancreatic cancer. Clinical trials have shown median survival extended to about 13.2 months versus roughly 6.7 months with chemotherapy. The drug will be available in the US with a roughly $39,800 monthly list price and expanded-access programmes have already treated thousands.
Arm Holdings chief executive Rene Haas says AI could one day help cure cancer, but the path is constrained by chip shortages and a demand surge for AI data centres. Multiple outlets report Haas’s remarks, framing a broaderAI-driven push in healthcare and manufacturing, while flagging supply constraints and broader market excitement.
The Guardian and The Scotsman analyze the evolving role of culture and arts funding in the UK. They highlight investments like Freelands’ £1.5m over five years to nurture art education and warn that cutting arts education infrastructure risks undermining community renewal and creative opportunity.
Three BBC investigations have revealed repeated failures in UK cancer care: a final review has found harm from misdiagnosis and inappropriate treatment by former Belfast neurologist Michael Watt; Coventry patients were prescribed temozolomide for years with little evidence of benefit; and England is missing cancer-treatment targets, with only 69.9% starting within 62 days. Officials and families are demanding answers.
Investors are recalibrating as AI executives urge caution on frontier development, sparking wide stock swings. A mix of weaker chip profits, higher oil prices and looming rate hikes are shaping a safer, slower AI era, while the potential IPOs and data-centre demand face renewed scrutiny.
Measles cases have surged nationwide with Pennsylvania reporting the highest tally this year. Health officials say vaccinations have risen, but distrust and political tensions are complicating containment. Fatalities from measles and related complications have occurred, including several unvaccinated individuals. The state faces hospitalizations and ongoing debates over public health responses.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
A wave of multi-million-dollar rounds in robotics and AI-enabled hardware signals a push to bring ‘physical AI’ into real-world production. Companies from Multiply Labs to FieldAI and SiMa.ai are racing to scale their robot-centric platforms, with strategic rounds aimed at forging scalable, cost-effective manufacturing and autonomous systems.